India, Nov. 11 -- Palisade Bio, Inc. (PALI) reported third-quarter 2026 financial results and provided a clinical development update for PALI-2108, its investigational oral therapy for inflammatory bowel disease (IBD).
The company has initiated its global Phase 2b ASCENTRA-UC trial in ulcerative colitis (UC), dosing the first patient on October 27, 2026.
Palisade has activated 29 of 30 planned U.S. clinical sites and is expanding the study globally toward approximately 115 sites.
ASCENTRA-UC is expected to enroll approximately 204 patients with moderately to severely active UC. The study is evaluating once-daily oral doses of PALI-2108 at 15 mg and 30 mg against placebo.
The primary endpoint is clinical remission at Week 12, measured us...